Free Trial
OTCMKTS:CPMV

Mosaic ImmunoEngineering Q4 2024 Earnings Results & Report

Mosaic ImmunoEngineering logo
$0.33 +0.27 (+432.80%)
As of 10/9/2026 12:56 PM Eastern

Mosaic ImmunoEngineering reported Q4 2024 earnings on April 15, 2025. The company reported EPS of -$0.02.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes

Mosaic ImmunoEngineering EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Mosaic ImmunoEngineering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Mosaic ImmunoEngineering Q4 2024 Earnings FAQ

Mosaic ImmunoEngineering (OTCMKTS:CPMV) reported earnings of -$0.02 per share for Q4 2024. The report was announced on Tuesday, April 15, 2025.

Mosaic ImmunoEngineering Earnings Headlines

Mosaic ImmunoEngineering Delays Annual 10-K Filing
Mosaic ImmunoEngineering, Inc. (CPMV) - Yahoo Finance
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, and predictions. He argues a simpler approach can work just as well. His free report, The Simple Path To Success With Options, breaks down a repeatable trade setup, common rookie mistakes, and step-by-step blueprints designed to cut through market noise. No complex charts. No guesswork. Just a straightforward setup anyone can learn.tc pixel
Mosaic ImmunoEngineering, Inc. (CPMV)
Mosaic Co.
See More Mosaic ImmunoEngineering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mosaic ImmunoEngineering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mosaic ImmunoEngineering and other key companies, straight to your email.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering (OTCMKTS:CPMV), Inc. is a biotechnology company focused on developing immunotherapies designed to stimulate the immune system to recognize and attack disease-related cells. Its work has centered primarily on therapeutic approaches for cancer and potentially other serious diseases.

The company’s activities have included research into multi-antigen immune-response technologies and vaccine-based therapies intended to activate T cells against selected targets. Publicly available information about its current development programs, commercial products, geographic operations and leadership is limited.

View Mosaic ImmunoEngineering Profile